Compare Docusign Inc (DOCU) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Docusign Inc vs Sanofi SA — how do they compare? Docusign Inc trades at $71.49 (market cap $13.35B), while Sanofi SA trades at $40.1 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 7.1× Docusign Inc's market cap, and Sanofi SA pays a 6.01% dividend while Docusign Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Docusign Inc for 71 Days and Sanofi SA for 94 Days on average.
| DOCU | SNY | |
|---|---|---|
Market Cap | $13.35B | $95.18B |
Volume | 3,158,858 | 2,995,646 |
Sector | Technology | Health |
52-Week High | $73.14 | $52.34 |
52-Week Low | $41.75 | $39.51 |
Typical Hold Time | 71 Days | 94 Days |
Enterprise Value | $12.76B | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DocuSign (DOCU) trades at $68.9, up 1.0% on the day, with a bullish technical outlook supported by moving averages. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $1.16 surpassing the $1.09 forecast. Revenue growth remains solid, reaching $2.98B in 2025, while profitability has improved significantly, with net income margin at 9.82%. Recent news highlights strong momentum, including a 50.8% stock surge over three months and leadership in IDC's integrated signing workflow software assessment (IDC MarketScape, August 2026).
The outlook for DOCU is cautiously optimistic, driven by AI-powered Intelligent Agreement Management adoption and operating leverage. However, risks include saturation in the e-signature market, insider selling activity, and a high P/E ratio of 42.01. Analyst consensus is mixed, with a Hold rating predominating (64.29%) and a price target of $68.75, slightly below the current price. Investors should weigh strong cash flow generation against valuation concerns and competitive pressures.
SNY trades at $40.2, up 1.62% on the day, with a bearish technical signal from moving averages but a neutral oscillator stance. The company reported revenue of $46.72B in 2025 with a net income margin of 16.72%, and it has beaten EPS estimates for the last three quarters. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling strong pipeline development.
The outlook is mixed; analyst consensus leans hold (51.86%) with a buy rating at 44.44%, reflecting optimism on new drug launches but caution over future profit margin compression projected for 2026. Key risks include execution of the expanded Regeneron partnership and managing debt levels amid investing cash flow volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Docusign Inc
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
